XENOTHERA announces the efficacy of its XAV-19 antibody against the BQ.1.1 variant
27 December 2022In the context of a major resurgence of the COVID epidemic, the French biotech XENOTHERA has just carried out an... View Article
In the context of a major resurgence of the COVID epidemic, the French biotech XENOTHERA has just carried out an... View Article
Naobios announced the signature of a Research License Agreement with Valneva to assess the EB66® cell line as cell substrate for the evaluation... View Article
This financing will further support the progress and expansion of OSE Immunotherapeutics’ lead clinical development programs in therapeutic areas with... View Article